p53 Allelotypes and enhanced detection of allelic loss in ovarian cancer: Lack of correlation with familial and clinical factors

Gynecologic Oncology

Volumn 61, Issue 2, 1996, Pages 180-188

  Skilling, J S ^a   Powills, K ^a   Lager, D J ^a   Anderson, B ^a   Sorosky, J ^a   Buller, R E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0029928117     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0122     Document Type: Article

References (52)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994, CA Cancer J. Clin. 44, 7-26 (1994).
2. Lynch, H. T., Watson, P., Bewtra, C., Conway, T. A., Hippee, C. R., Kaur, P., and Lynch, J. F. Hereditary ovarian cancer: Heterogeneity in age at diagnosis, Cancer 67, 1460-1466 (1991).
3. Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., Cavalieri, R. J., and Boland, C. R. Genetics, natural history, tumor spectrum, and pathology of hereditary non-polyposis colorectal cancer: An updated review, Gastroenterology 104, 1535-1549 (1993).
4. Buller, R. E., Anderson, B., Connor, J. P., and Robinson, R. Familial ovarian cancer, Gynecol. Oncol. 51, 160-166 (1993).
5. Buller, R. E., Niemann, T., Connor, J. P., Squatrito, R. C., Skilling, J. S., and Anderson, B. Isolation and preliminary characteristics of an ovarian carcinoma cell line from a patient with familial ovarian cancer, Gynecol. Oncol. 56, 39-44 (1995).
6. Phillips, N., Ziegler, M., Saha, B., and Xyons, F. Allelic loss on chromosome 17 in human ovarian cancer, Int. J. Cancer 54, 85-91 (1993).
7. Lee, J. H., Kavanagh, J. J., Wildrick, D. M., Wharton, J. T., and Blick, M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas, Cancer Res. 50, 2724-2728 (1990).
8. Eccles, D. M., Cranston, G., Steel, C. M., Nakamura, Y., and Leonard, R. C. F. Allele losses on chromosome 17 in human epithelial ovarian carcinoma, Oncogene 5, 1599-1601 (1990).
9. Yang-Feng, T. L., Li, S., Han, H., and Schwartz, P. E. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer, Int. J. Cancer 52, 575-580 (1992).
10. Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M., and Welsh, D. The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in tumorigenesis, Br. J. Cancer 69, 409-416 (1994).
11. Hann, C. B., and Lane, D. P. The dominating effect of p53, Nature Genet. 9, 221-222 (1995).
12. Malkin, D. p53 and the Li-Fraumeni syndrome, Cancer Genet. Cytogenet. 66, 83-92 (1993).
13. Buller, R. E., Skilling, J. S., Kaliszewski, S., Niemann, T., and Anderson, B. Absence of significant germ line p53 mutations in ovarian cancer patients, Gynecol. Oncol. 58, 368-374 (1995).
14. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types, Nature 342, 705-708 (1989).
15. Harris, C. C., and Holstein, M. Clinical implications of the p53 tumor-suppressor gene, N. Engl. J. Med. 329(18), 1318-1327 (1993).
16. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res. 54, 4855-4878 (1994).
17. Knudson, A. G., Jr. Mutation and cancer: Statistical study of retinoblastoma, Proc. Natl. Acad. Sci. USA 68, 820-823 (1971).
18. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. p53 gain of function mutations, Nature Genet. 4, 42-46 (1993).
19. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., and Donehauer, L. A. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice, Nature Genet. 9(3), 305-311 (1995).
20. Okamoto, A., Sameshima, Y., Yokoyama, S., Terashima, Y., Sugimura, T., Terada, M., and Yokota, J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer, Cancer Res. 51, 5171-5176 (1991).
21. Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., Jr., and Berchuck, A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer, J. Natl. Cancer Inst. 85(18), 1513-1519 (1993).
22. Mazars, R., Pujol, P., Maudelonde, T., Jeanteur, P., and Theillet, C. p53 mutations in ovarian cancer: A late event? Oncogene 6, 1685-1690 (1991).
23. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer, Proc. Natl. Acad. Sci. USA 90, 4961-4965 (1993).
24. Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., and Hirohashi, S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy, Jpn. J. Cancer Res. 83, 978-984 (1992).
25. Mok, C-H., Tsao, S-W., Knapp, R. C., Fishbaugh, P. M., and Lau, C. C. Unifocal origin of advanced human epithelial ovarian cancers, Cancer Res. 52, 5119-5122 (1992).
26. Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, H. C., Leonard, R. C. F., Kelly, K. F., Parkin, D. E., and Haites, N. E. p53 mutation is a common genetic event in ovarian carcinoma, Cancer Res. 53, 2128-2132 (1993).
27. Naito, M., Satake, M., Sakai, E., Hirano, Y., Tsuchida, N., Kanzaki, H., Ito, Y., and Mori, T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis, Jpn. J. Cancer Res. 83, 1030-1036 (1992).
28. Fujita, M., Enomoto, T., Inoue, M., Tanizawa, O., Ozaki, M., Rice, J. M., and Nomura, T. Alteration of the p53 tumor suppressor gene occurs independently of k-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary, Jpn. J. Cancer Res. 85, 1247-1256 (1994).
29. McManus, D. T., Yap, E. P. H., Maxwell, P., Russell, S. E. H., Toner, P. G., and McGee, J. O'D. p53 expression, mutation, and allelic deletion in ovarian cancer, J. Pathol. 174, 159-168 (1994).
30. Sheridan, E., Silcochs, P., Smith, J., Hancock, B. W., and Goyns, M. H. p53 mutations in a series of epithelial ovarian cancers from the V.K., and its prognostic significance, Eur. J. Cancer 30A(11), 1701-1704 (1994).
31. Kim, J. W., Cho, Y. H., Kwon, D. J., Kim, T. E., Park, T. C., Lee, J. M., and Namkoong, S. E. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma, Gynecol. Oncol. 57, 199-204 (1995).
32. Niwa, K., Itoh, M., Munose, T., Morishita, S., Itoh, N., Mori, H., and Tamaya, T. Alteration of the p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance, Br. J. Cancer 70(6), 1191-1197 (1994).
33. Teneriello, M. G., Ebina, M., Linnoila, R. I., Henry, M., Nash, J. D., Park, R. C., and Birrer, M. J. p53 and ki-ras gene mutations in epithelial ovarian neoplasms, Cancer Res. 53, 3103-3108 (1993).
34. Klemi, P. J., Pylkkanen, L., Kiilholma, P., Kurvinen, K., and Joenseuu, H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma, Cancer 76, 1201-1208 (1995).
35. Futreal, P. A., Barrett, J. C., and Wiseman, R. W. An alu polymorphism intragenic to the TP53 gene, Nucleic Acids Res. 19(24), 6977 (1991).
36. Lazar, V., Hazard, F., Bertin, F., Janin, N., Bellet, D., and Bressac, B. Simple sequence repeat polymorphism within the p53 gene, Oncogene 8(6), 1703-1705 (1993).
37. Buchman, V. L., Chumakov, P. M., Ninkina, O. P., and Georgiev, G. P. A variation in the structure of the protein-coding region of the human p53 gene, Gene 70, 245-252 (1988).
38. McDaniel, T., Carbone, D., Takahashi, T., Chumakov, P., Chang, E. H., Pirollo, K. F., Yin, J., Huang, V., and Melteer, S. J. The MSP1 polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products, Nucleic Acids Res. 19(17), 4796 (1991).
39. Floderus, B., Barlow, L., and Mack, T. M. Recall bias in subjective reports of familial cancer, Epidemiology 1, 318-321 (1990).
40. Slattery, M. L., and Kerber, R. A. A comprehensive evaluation of family history and breast cancer risk, JAMA 270, 1563-1568 (1993).
41. Skilling, J. S., Squatrito, R. C., Connor, J. P., Niemann, T., Terrell, K., and Buller, R. E. p53 gene mutation analysis and antisense mediated growth inhibition of human ovarian carcinoma cell lines, Gynecol. Oncol. 60, 72-80 (1996).
42. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., and Hayashi, S-I. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer, Carcinogenesis 14, 1085-1089 (1993).
43. Jones, H. M., and Nakamura, Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism, Genes Chromosomes Cancer 5, 89-90 (1992).
44. Skilling, J. S., Knowlton, S., Powills, K., Anderson, B., Sorosky, J., and Buller, R. E. p53 deletions, insertions, and splice-junction abnormalities in ovarian cancer reflect a high degree of genomic instability, Proc. Am. Assoc. Cancer Res. 36, 567 (3377), (1995).
45. Runnebaum, I. B., Tong, X. W., Konig, R., Hong, Z., Korver, K., Atkinson, E. N., Kreienberg, R., and Kieback, D. G. p53-based blood test for p53IN3 and risk for sporadic ovarian cancer, Lancet 345, 994 (1995).
46. Ara, S., Lee, P. S. Y., Hansen, M. F., and Saya, H. Codon 72 polymorphism of the TP53 gene, Nucleic Acids Res. 18, 4961 (1990).
47. Olschwang, S., Laurent-Puig, P., Vassal, A., Salmon, R. J., and Thomas, G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonie cancer patients and a control population, Hum. Genet. 86, 369-370 (1991).
48. Chumakov, P. M., and Jenkins, J. R. BstN1/Nei1 polymorphism of the human p53 gene (TP53), Nucleic Acids Res. 19(24), 6969 (1991).
49. de la Calli-Marten, O., Romero, M., Fabregst, V., Ercilla, G., Vives, J., and Yagüe, J. MSP1 polymorphism of the human p53 gene, Nucleic Acids Res. 18(16), 4963 (1990).
50. Lane, D. P. p53, guardian of the genome, Nature 358, 15-16 (1992).
51. Vidal-Pulg, A., and Moller, D. E. Comparative sensitivity of alternative single strand conformation polymorphism (SSCP) methods, Biotechniques 17, 490-496 (1994).
52. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53 dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell 74, 957-967 (1993).